Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.6000 (2.19%) ($5.6000 - $5.6000) on Thu. Mar. 18, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.16% (three month average) | RSI | 64 | Latest Price | $5.6000(2.19%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 1.9% a day on average for past five trading days. | Weekly Trend | ADMS advances 4.6% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) BND(39%) CEMB(39%) IBUY(37%) BOTZ(34%) BWX(33%) | Factors Impacting ADMS price | ADMS will decline at least -2.58% in a week (0% probabilities). UUP(-39%) VXX(-33%) VIXM(-24%) TBT(-10%) UNG(-4%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.58% (StdDev 5.16%) | Hourly BBV | 0.3 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $5.36(4.48%) | 10 Day Moving Average | $5.15(8.74%) | 20 Day Moving Average | $5.11(9.59%) | To recent high | -15.9% | To recent low | 12% | Market Cap | $158m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |